author-photo

Takahiro Kogawa

University of Texas MD Anderson Cancer Center

66

Papers

488

Citations

Citation Trend

Filter By

Papers (47) Sort By

Journal Conference Others

LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.

2021 Anticancer Research
Show All
- Source
- Cite
- Save
Citations (0)
The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis

2021 The Breast
Show All
- Source
- Cite
- Save
Citations (0)
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.

2021 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (1)
Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.

2021 in Vivo
Show All
- Source
- Cite
- Save
Citations (0)
A Phase II Study of Talimogene Laherparepvec for Patients With Inoperable Locoregional Recurrence of Breast Cancer

2021
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab

2020 Oncologist
Show All
- Source
- Cite
- Save
Citations (1)
Abstract OT1-07-06: Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)

2020 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (0)
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.

2020 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (3)